Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Hormone Molecular Biology and Clinical Investigation

Editor-in-Chief: Chetrite, Gérard S.

Editorial Board: Alexis, Michael N. / Baniahmad, Aria / Beato, Miguel / Bouillon, Roger / Brodie, Angela / Carruba, Giuseppe / Chen, Shiuan / Cidlowski, John A. / Clarke, Robert / Coelingh Bennink, Herjan J.T. / Darbre, Philippa D. / Drouin, Jacques / Dufau, Maria L. / Edwards, Dean P. / Falany, Charles N. / Fernandez-Perez, Leandro / Ferroud, Clotilde / Feve, Bruno / Flores-Morales, Amilcar / Foster, Michelle T. / Garcia-Segura, Luis M. / Gastaldelli, Amalia / Gee, Julia M.W. / Genazzani, Andrea R. / Greene, Geoffrey L. / Groner, Bernd / Hampl, Richard / Hilakivi-Clarke, Leena / Hubalek, Michael / Iwase, Hirotaka / Jordan, V. Craig / Klocker, Helmut / Kloet, Ronald / Labrie, Fernand / Mendelson, Carole R. / Mück, Alfred O. / Nicola, Alejandro F. / O'Malley, Bert W. / Raynaud, Jean-Pierre / Ruan, Xiangyan / Russo, Jose / Saad, Farid / Sanchez, Edwin R. / Schally, Andrew V. / Schillaci, Roxana / Schindler, Adolf E. / Söderqvist, Gunnar / Speirs, Valerie / Stanczyk, Frank Z. / Starka, Luboslav / Sutter, Thomas R. / Tresguerres, Jesús A. / Wahli, Walter / Wildt, Ludwig / Yang, Kaiping / Yu, Qi


CiteScore 2018: 2.43

SCImago Journal Rank (SJR) 2018: 0.947
Source Normalized Impact per Paper (SNIP) 2018: 0.837

Online
ISSN
1868-1891
See all formats and pricing
More options …
Volume 35, Issue 1

Issues

Evaluation in the predictive value of serum human epididymal protein 4 (HE4), cancer antigen 125 (CA 125) and a combination of both in detecting ovarian malignancy

Beng Hock Teh / Soon Leong YongORCID iD: http://orcid.org/0000-0003-2836-0756 / Wee Wee Sim / Kim Bee Lau / Haris Njoo Suharjono
Published Online: 2018-07-31 | DOI: https://doi.org/10.1515/hmbci-2018-0029

Abstract

Background

This study was conducted to evaluate the performance of human epididymal protein 4 (HE4), cancer antigen 125 (CA 125) and a combination of both via the Risk of Ovarian Malignancy Algorithm (ROMA) in detecting ovarian malignancy.

Methods

This was a diagnostic study enrolling 129 patients with pelvic mass(es) suspected of originating in the ovary who had been scheduled for surgery or radiological-guided biopsy. Serum HE4 and CA 125 levels were measured. HE4, CA 125 and ROMA were evaluated for sensitivity, specificity, positive predictive value and negative predictive value. The receiver operating characteristic (ROC) plots were graphed and area under the curve (AUC) values were calculated to investigate the accuracy of each marker for predicting ovarian malignancy.

Results

Overall, CA 125 remained significantly more sensitive (88.9% vs. 51.9%, p = 0.006) but less specific (56.9% vs. 95.1%, p < 0.001) than HE4. HE4 was superior to CA 125 in specificity (97.7% vs. 54.5%, p < 0.001) for premenopausal women. ROMA was non-significantly more sensitive (100.0% vs. 92.3%, p = 1.000) than CA 125 but both were equally specific (71.4%) for the postmenopausal group. In the premenopausal group, the AUC of serum HE4 was higher than serum CA 125 (0.851 vs. 0.817) but was equivalent to ROMA (0.851 vs. 0.859). In the postmenopausal group, ROMA exhibited an excellent AUC value as compared to CA 125 and HE4 (AUC of 0.907 vs. 0.874 vs. 0.863, respectively).

Conclusion

HE4 is useful in ruling out ovarian malignancy among premenopausal women. For postmenopausal women, ROMA appears to be an all-rounder with overall good sensitivity and specificity.

Keywords: CA 125; HE4; ovarian cancer; pelvic mass; ROMA

References

  • [1]

    Omar ZA, Tamin NS. National Cancer Registry Report. Malaysia Cancer Statistics – Data and Figure 2007. Malaysia: National Cancer Registry, Ministry of Health, Malaysia, 2011.Google Scholar

  • [2]

    Jacobs I, Stabile I, Bridges J, Kemsley P, Reynolds C, Grudzinskas J, et al. Multimodal approach to screening for ovarian cancer. Lancet. 1988;1:268–71.PubMedGoogle Scholar

  • [3]

    Jacobs I, Bast RC Jr. The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod. 1989;4:1–12.CrossrefPubMedGoogle Scholar

  • [4]

    Schummer M, Ng WV, Bumgarner RE, Nelson PS, Schummer B, Bednarski DW, et al. Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas. Gene. 1999;238:375–85.PubMedCrossrefGoogle Scholar

  • [5]

    Hellström I, Raycraft J, Hayden-Ledbetter M, Ledbetter JA, Schummer M, McIntosh M, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res. 2003;63:3695–700.PubMedGoogle Scholar

  • [6]

    Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol. 2008;108:402–8.PubMedWeb of ScienceCrossrefGoogle Scholar

  • [7]

    Moore RG, McMeekin DS, Brown AK, DiSilvestro P, Miller MC, Allard WJ, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol. 2009;112:40–6.CrossrefWeb of SciencePubMedGoogle Scholar

  • [8]

    Moore RG, Miller MC, Disilvestro P, Landrum LM, Gajewski W, Ball JJ, et al. Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass. Obstet Gynecol. 2011;118:280–8.Web of ScienceCrossrefPubMedGoogle Scholar

  • [9]

    Huhtinen K, Suvitie P, Hiissa J, Junnila J, Huvila J, Kujari H, et al. Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br J Cancer. 2009;100:1315–9.PubMedWeb of ScienceCrossrefGoogle Scholar

  • [10]

    Bandiera E, Romani C, Specchia C, Zanotti L, Galli C, Ruggeri G, et al. Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management. Cancer Epidemiol Biomarkers Prev. 2011;20:2496–506.PubMedCrossrefWeb of ScienceGoogle Scholar

  • [11]

    Havrilesky LJ, Whitehead CM, Rubatt JM, Cheek RL, Groelke J, He Q, et al. Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence. Gynecol Oncol. 2008;110:374–82.Web of ScienceCrossrefPubMedGoogle Scholar

  • [12]

    Holcomb K, Vucetic Z, Miller MC, Knapp RC. Human epididymis protein 4 offers superior specificity in the differentiation of benign and malignant adnexal masses in premenopausal women. Am J Obstet Gynecol. 2011;205:358 e1–6.Web of ScienceCrossrefGoogle Scholar

  • [13]

    Montagnana M, Danese E, Ruzzenente O, Bresciani V, Nuzzo T, Gelati M, et al. The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful? Clin Chem Lab Med. 2011;49:521–5.Web of SciencePubMedGoogle Scholar

  • [14]

    Van Gorp T, Cadron I, Despierre E, Daemen A, Leunen K, Amant F, et al. HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the risk of ovarian malignancy algorithm. Br J Cancer. 2011;104:863–70.PubMedWeb of ScienceCrossrefGoogle Scholar

  • [15]

    Anton C, Carvalho FM, Oliveira EI, Maciel GA, Baracat EC, Carvalho JP. A comparison of CA125, HE4, risk ovarian malignancy algorithm (ROMA), and risk malignancy index (RMI) for the classification of ovarian masses. Clinics. 2012;67:437–41.Web of ScienceCrossrefGoogle Scholar

  • [16]

    Karlsen MA, Sandhu N, Høgdall C, Christensen IJ, Nedergaard L, Lundvall L, et al. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass. Gynecol Oncol. 2012;127:379–83.Web of ScienceCrossrefPubMedGoogle Scholar

  • [17]

    Sandri MT, Bottari F, Franchi D, Boveri S, Candiani M, Ronzoni S, et al. Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: correlation with pathological outcome. Gynecol Oncol. 2013;128:233–8.Web of SciencePubMedCrossrefGoogle Scholar

  • [18]

    Richards A, Herbst U, Manalang J, Pather S, Saidi S, Tejada-Berges T, et al. HE4, CA125, the risk of malignancy algorithm and the risk of malignancy index and complex pelvic masses – a prospective comparison in the pre-operative evaluation of pelvic masses in an Australian population. Aust N Z J Obstet Gynaecol. 2015;55:493–7.Web of ScienceCrossrefGoogle Scholar

  • [19]

    Wang S, Dong L, Li H, Wang M. The application of HE4 in diagnosis of gynecological pelvic malignant tumor. Clin Oncol Cancer Res. 2009;6:72–4.Google Scholar

  • [20]

    Fujiwara H, Suzuki M, Takeshima N, Takizawa K, Kimura E, Nakanishi T, et al. Evaluation of human epididymis protein 4 (HE4) and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools of type I and type II epithelial ovarian cancer in Japanese women. Tumour Biol. 2015;36:1045–53.PubMedCrossrefGoogle Scholar

  • [21]

    Kim YM, Whang DH, Park J, Kim SH, Lee SW, Park HA, et al. Evaluation of the accuracy of serum human epididymis protein 4 in combination with CA125 for detecting ovarian cancer: a prospective case-control study in a Korean population. Clin Chem Lab Med. 2011;49:527–34.Web of ScienceGoogle Scholar

  • [22]

    Chung SH, Lee SY, Ju W, Kim SC. Clinical efficacy of serum human epididymis protein 4 as a diagnostic biomarker of ovarian cancer: A pilot study. Obstet Gynecol Sci. 2013;56:234–41.CrossrefPubMedGoogle Scholar

  • [23]

    Chan KK, Chen CA, Nam JH, Ochiai K, Wilailak S, Choon AT, et al. The use of HE4 in the prediction of ovarian cancer in Asian women with a pelvic mass. Gynecol Oncol. 2013;128:239–44.PubMedWeb of ScienceCrossrefGoogle Scholar

  • [24]

    Nassir M, Darb-Esfahani S, Richter R, Chekerov R, Hall C, Muallem MZ, et al. HE4 tissue expression in borderline ovarian tumors: a pilot study by the Tumorbank Ovarian Cancer Network. Anticancer Res. 2013;33:1673–7.PubMedGoogle Scholar

  • [25]

    Braicu EI, Van Gorp T, Nassir M, Richter R, Chekerov R, Gasimli K, et al. Preoperative HE4 and ROMA values do not improve the CA125 diagnostic value for borderline tumors of the ovary (BOT) – a study of the TOC Consortium. J Ovarian Res. 2014;7:49.Web of ScienceCrossrefGoogle Scholar

About the article

Received: 2018-04-29

Accepted: 2018-06-19

Published Online: 2018-07-31


Author Statement

Research funding: This was a self-funded research using department’s own source of funds. No grant number applied.

Conflict of interest: The authors declare that they have no conflicts of interest. Roche Diagnostics (Malaysia) Sdn. Bhd. provided the Elecsys HE4 and CA 125 II reagent kits for the purpose of this research project. However, the company had no involvement or input in the study design, data collection, statistical analysis, data interpretation or preparation of manuscript. None of the authors received any form of personal gifts or compensation from Roche Diagnostics (Malaysia) Sdn. Bhd.

Informed consent: Informed consent has been obtained from all participants.

Ethical approval: The research related to human use complies with all the relevant national regulations and institutional policies, was performed in accordance with the tenets of the Helsinki Declaration. This study had been registered to National Medical Research Register (under Ministry of Health Malaysia) and ethical approval for this research was obtained from Medical Research and Ethics Committee, Ministry of Health Malaysia. The Research Identification Number given was NMRR-13-380-15355.

Submission declaration: This study had been presented at the 5th Scientific Meeting of Obstetrics and Gynaecology UKM Medical Centre and the 24th Congress of the Obstetrical and Gynaecological Society of Malaysia on 9th April 2016 and 3rd June 2016, respectively.


Citation Information: Hormone Molecular Biology and Clinical Investigation, Volume 35, Issue 1, 20180029, ISSN (Online) 1868-1891, DOI: https://doi.org/10.1515/hmbci-2018-0029.

Export Citation

©2018 Walter de Gruyter GmbH, Berlin/Boston.Get Permission

Comments (0)

Please log in or register to comment.
Log in